Accreditation
ACC.19 Statement of Educational Need/Purpose

Despite tremendous advances in recent years, cardiovascular disease (CVD) remains the leading cause of death throughout the world. While ongoing research seeks to further improve outcomes in several areas of CVD, numerous well-defined, evidence-based practices face struggles with implementation.

It is imperative that every member of the cardiovascular team play their role(s) to address these practice gaps and optimize cardiovascular care. Therefore, in this era of rapid transformation, education is essential to update clinicians on the latest science and advances in CVD, facilitate uptake of evolving best practices, and promote practical solutions that support the entire care team.

ACC.19 will provide an engaging and empowering educational environment that offers a contemporary environmental scan, state-of-the-art updates, expert perspectives on challenging clinical decisions, and tools to help clinicians navigate real-world challenges with the collective goal of improving outcomes for patients with cardiovascular disease.

  Educational Program Goals
  Educational Program Goals

To provide a stimulating environment for information sharing of new knowledge, presentation of research, networking and collaboration with a goal of improving cardiovascular disease management for all patients

  • To facilitate translation of cardiovascular science to all members of the care team leading to high-quality, patient-centered care
  • To allow for examination and discussion of important contributions and controversies in cardiovascular care
  • To integrate traditional and novel educational techniques and create an interactive and informative learning environment
  • To promote cardiovascular science and education to a global audience
  Credit Information
  Credit Information

Physicians

The American College of Cardiology Foundation (ACCF) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ACCF designates this live activity for a maximum of 28 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC

Cardiology Magazine Image

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 28 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

European Board for Accreditation in Cardiology (EBAC) External CME Credit

Cardiology Magazine Image

ACC.19 will be accredited by the European Board for Accreditation in Cardiology (EBAC) for 20 hours of External CME credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME) and the European Board for Accreditation in Cardiology (EBAC) have recognized each other's accreditation systems as substantially equivalent. Apply for credit through the post-course evaluation.

Nurses

The American College of Cardiology Foundation (ACCF) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation (ANCC Provider Number 0019).

The ACCF designates this educational activity for a maximum of 28 continuing nursing education contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Cardiology Magazine Image

Pharmacists

This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

  ACC.19 Learning Objectives
  ACC.19 Learning Objectives
  Acute and Stable Ischemic Heart Disease
  Acute and Stable Ischemic Heart Disease

As a result of participating in the Acute and Stable Ischemic Heart Disease Pathway sessions, learners will have an improved or reinforced ability to:

  1. Compare and contrast different STEMI and NSTEMI systems of care and logistical processes for managing complex patients with ACS
  2. Formulate a differential diagnosis and management strategy for athletes presenting with ischemic heart disease
  3. Scrutinize the methodology of recent acute and stable ischemic heart disease clinical trials to determine the implications and generalizability of findings
  4. Evaluate the evidence and different perspectives underlying current controversies in acute and stable ischemic heart disease diagnosis and management and ACS Guidelines, including international and other societal guidelines
  5. Describe the management of complications seen in ischemic heart diseases
  6. Discuss barriers to implementation of cardiac rehab and novel approaches
  7. Assess and appropriately manage patients with cardiogenic shock or in need of critical care
  8. Detect and manage patients with angina refractory that are resistant to conventional treatment options
  9. Identify the diagnosis and management of atypical ischemic heart disease presentations, including microvascular dysfunction, spontaneous coronary artery dissection, and ischemia without obstructive coronary artery disease
  10. Recognize cutting-edge approaches towards genetic testing for coronary artery disease
  Arrhythmias and Clinical EP
  Arrhythmias and Clinical EP

As a result of participating in the Arrhythmias and Clinical EP Pathway sessions, learners will have an improved or reinforced ability to:

  1. Apply recent evidence and current guideline recommendations to the management of arrhythmias
  2. Integrate emerging evidence and options for prevention, detection, risk assessment, rhythm and rate management, and stroke prevention into the care of patients with atrial fibrillation
  3. Compare and contrast pharmacologic management and treatment of arrhythmias, including outcomes and risk of adverse events due to medications used to treat arrhythmias
  4. Identify patients and patient populations who can benefit from currently available device-based therapies
  5. Recognize and interpret salient ECG patterns and integrate into clinical decision-making
  6. Evaluate symptoms (eg. syncope) that arise due to arrhythmias in special populations, including in athletes, inherited arrhythmia conditions, pregnancy, and cardiomyopathy/heart failure
  7. Evaluate current findings from clinical trials and future implications in research
  8. Debate topical health trends and advancing technology utilized by both clinicians and patients, and implication on diagnosis and management of arrhythmias
  Congenital Heart Disease
  Congenital Heart Disease

As a result of participating in the Congenital Heart Disease (CHD) Pathway sessions, learners will have an improved or reinforced ability to:

  1. Identify strategies to effectively evaluate and manage acquired pediatric heart disease
  2. Discuss innovative therapies and complex clinical scenarios in fetal cardiology
  3. Describe the role of novel transcatheter therapies and surgical techniques in the management of CHD
  4. Critically evaluate emerging imaging applications in CHD
  5. Incorporate recent advances and research into cardiology practice for CHD
  6. Explore challenging issues in heart failure management and electrophysiology in children and adults
  7. Review the contemporary management of pregnancy and other women's health issues in patients with CHD
  Heart Failure and Cardiomyopathy
  Heart Failure and Cardiomyopathy

As a result of participating in the Heart Failure and Cardiomyopathies Pathway sessions, learners will have an improved or reinforced ability to:

  1. Integrate contemporary concepts in cardiovascular pathophysiology with evidence-based strategies in the diagnosis, evaluation, and management across the entire spectrum of patients with heart failure and cardiomyopathy
  2. Offer practical guidance on diet, exercise, support, and heart failure management that is appropriately tailored to diverse patient populations across various stages and types of heart failure
  3. Recognize the interaction between various comorbidities and heart failure, and best practices in the multidisciplinary approach
  4. Evaluate the role and indications for ICDs, CRTs, hemodynamic sensors, and mechanical support for heart failure management
  5. Expand knowledge in the evidence-based care of patients with infiltrative and inherited cardiomyopathy, and less common inherited and acquired cardiomyopathies
  6. Analyze the evidence on current and newer pharmacotherapies, devices, and therapies for best practices heart failure management
  7. Discuss future approaches to heart failure and cardiomyopathy diagnosis and management
  8. Develop insight to address the needs of specific patient populations with heart failure and cardiomyopathy, and at different stages of life
  Invasive CV Angiography and Intervention
  Invasive CV Angiography and Intervention

As a result of participating in the Invasive CV Angiography and Intervention Pathway sessions, learners will have an improved or reinforced ability to:

  1. Determine an appropriate antithrombotic regimen for diverse patients with acute coronary syndrome or undergoing a revascularization procedure, and address issues with antiplatelet regimens in patients at high risk for bleeding
  2. Interpret and integrate findings from adjunctive coronary and endovascular assessment into clinical decision-making
  3. Decide whether and how to revascularize patients who are high-risk or have complex coronary artery disease
  4. Evaluate the evidence from clinical trials describing outcomes, recent advances, and expanded applications of angiography and interventional cardiology
  5. Describe key tactics for preventing and managing interventional complications
  6. Appropriately incorporate new and state-of-the-art structural heart and endovascular technologies and techniques into patient care
  7. Work effectively as part of a comprehensive care team to manage patients before, during, and after interventional procedures
  8. Apply findings from diagnostic imaging to plan treatment, guide intervention, and gauge procedural outcomes
  Non-Invasive Imaging
  Non-Invasive Imaging

As a result of participating in the Non-Invasive Imaging Pathway sessions, learners will have an improved or reinforced ability to:

  1. Apply current imaging guidelines for the assessment of valvular, myocardial, coronary, pericardial, and complex congenital and structural heart diseases
  2. Identify both current and emerging roles of stress echocardiography for evaluating heart diseases
  3. Evaluate recent innovations in advanced imaging techniques and their potential applications
  4. Utilize findings from non-invasive imaging to clarify the etiology and guide the management of patients with heart failure or cardiomyopathy and systemic diseases involving the heart (e.g., cardiac amyloidosis, sarcoidosis)
  5. Recognize the prognostic implications of cardiac CT and cardiac MRI findings and their appropriate impact on patient management
  Prevention
  Prevention

As a result of participating in the Prevention Pathway sessions, learners will have an improved or reinforced ability to:

  1. Apply current evidence base to determine thresholds for hypertension treatment, establish therapeutic goals, and implement team-based processes to achieve blood pressure control in simple and complex cases
  2. Recognize the implications of diabetes on cardiovascular disease and tailor management strategies based on available evidence
  3. Evaluate the underlying evidence on dyslipidemia and ASCVD, including targeting novel pathways and the controversies in dyslipidemia management.
  4. Integrate best practices with regards to lifestyle and dietary recommendations to prevent or manage ASCVD and related diseases, such as diabetes
  5. Consider unique factors in prevention and management of ASCVD for vulnerable populations and the disparities in current research and guidelines
  6. Apply current cholesterol and other ASCVD prevention guidelines in practice
  Pulmonary Hypertension and Venous Thromboembolic Disease
  Pulmonary Hypertension and Venous Thromboembolic Disease

As a result of participating in the Pulmonary Hypertension and Venous Thromboembolic Disease Pathway sessions, learners will have an improved or reinforced ability to:

  1. Evaluate the diagnostic and therapeutic options for patients with pulmonary hypertension and the multiple potential etiologies of pulmonary hypertension
  2. Identify innovative translational discoveries and the potential for personalized medicine in PAH
  3. Apply current practice and innovative research to the cardiology practice for patient population with VTE
  4. Utilize shared decision making and adjunctive resources in caring for patients with pulmonary hypertension
  Valvular Heart Disease
  Valvular Heart Disease

As a result of participating in Valvular Heart Disease (VHD) Pathway sessions, learners will have an improved or reinforced ability to:

  1. Apply recent updates to guidelines and recommend best practices for valvular care to clinical practice
  2. Recognize how the mechanism, natural history, diagnosis and treatment options of patients with valve disease continue to evolve and affect patient care algorithms
  3. Assess the role of imaging and physiologic testing in characterizing valvular disease and guiding management
  4. Incorporate the heart team approach to treatment of patients with VHD
  5. Incorporate the evidence on contemporary diagnostic and treatment options into clinical decision-making for patients with VHD
  6. Compare strategies in assessment, diagnosis and treatment of special populations with valvular heart disease
  Vascular Medicine
  Vascular Medicine

As a result of participating in Vascular Medicine Pathway sessions, learners will have an improved or reinforced ability to:

  1. Evaluate the evidence associated with current management of vascular diseases
  2. Incorporate recent clinical trial findings and evidence-based guideline recommendations into the treatment of patients with vascular disease, including special populations
  3. Recognize effective treatment of common vascular and thrombotic complications of cancer and cancer-directed therapy
ACC Logo
ACC.19 on Social Media:
      
2018 American College of Cardiology Foundation. Visit ACC.org
Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Cookie Policy Contact Us